BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Itoh S, Yoshizumi T, Yugawa K, Imai D, Yoshiya S, Takeishi K, Toshima T, Harada N, Ikegami T, Soejima Y, Kohashi K, Oda Y, Mori M. Impact of Immune Response on Outcomes in Hepatocellular Carcinoma: Association With Vascular Formation. Hepatology 2020;72:1987-99. [PMID: 32112577 DOI: 10.1002/hep.31206] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 13.0] [Reference Citation Analysis]
Number Citing Articles
1 Li LQ, Zhang LH, Zhang Y, Lu XC, Zhang Y, Liu YK, Khader MA, Jia-Wen, Tao-Liu, Li JZ. Construction of immune-related gene pairs signature to predict the overall survival of osteosarcoma patients. Aging (Albany NY) 2020;12:22906-26. [PMID: 33203792 DOI: 10.18632/aging.104017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
2 Yugawa K, Itoh S, Iseda N, Kurihara T, Kitamura Y, Toshima T, Harada N, Kohashi K, Baba S, Ishigami K, Oda Y, Yoshizumi T, Mori M. Obesity is a risk factor for intrahepatic cholangiocarcinoma progression associated with alterations of metabolic activity and immune status. Sci Rep 2021;11:5845. [PMID: 33712681 DOI: 10.1038/s41598-021-85186-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Lu L, Wei W, Huang C, Li S, Zhong C, Wang J, Yu W, Zhang Y, Chen M, Ling Y, Guo R. A new horizon in risk stratification of hepatocellular carcinoma by integrating vessels that encapsulate tumor clusters and microvascular invasion. Hepatol Int 2021;15:651-62. [PMID: 33835379 DOI: 10.1007/s12072-021-10183-w] [Reference Citation Analysis]
4 Xue JS, Liu H, Meng GX, Ding ZN, Yan LJ, Yao SY, Li HC, Dong ZR, Chen ZQ, Hong JG, Li T. Prognostic value of soluble programmed cell death-1 (sPD-1) and soluble programmed cell death ligand-1 (sPD-L1) for hepatocellular carcinoma: a systematic review and meta-analysis. Cancer Immunol Immunother 2021. [PMID: 34750662 DOI: 10.1007/s00262-021-03103-2] [Reference Citation Analysis]
5 Xia X, Tang P, Liu H, Li Y. Identification and Validation of an Immune-related Prognostic Signature for Hepatocellular Carcinoma. J Clin Transl Hepatol 2021;9:798-808. [PMID: 34966643 DOI: 10.14218/JCTH.2021.00017] [Reference Citation Analysis]
6 Lei Y, Li X, Huang Q, Zheng X, Liu M. Progress and Challenges of Predictive Biomarkers for Immune Checkpoint Blockade. Front Oncol 2021;11:617335. [PMID: 33777757 DOI: 10.3389/fonc.2021.617335] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
7 Liu G, Wu D, Wen Y, Cang S. Immune-associated molecular occurrence and prognosis predictor of hepatocellular carcinoma: an integrated analysis of GEO datasets. Bioengineered 2021;12:5253-65. [PMID: 34424809 DOI: 10.1080/21655979.2021.1962147] [Reference Citation Analysis]
8 Yan Q, Zheng W, Wang B, Ye B, Luo H, Yang X, Zhang P, Wang X. A prognostic model based on seven immune-related genes predicts the overall survival of patients with hepatocellular carcinoma. BioData Min 2021;14:29. [PMID: 33962640 DOI: 10.1186/s13040-021-00261-y] [Reference Citation Analysis]
9 Itoh S, Yugawa K, Yoshizumi T, Oda Y, Mori M. Immune microenvironment in primary and metastatic liver cancers. Hepatol Res 2021;51:3-4. [PMID: 33354891 DOI: 10.1111/hepr.13607] [Reference Citation Analysis]
10 Xie C, Wu H, Pan T, Zheng X, Yang X, Zhang G, Lian Y, Lin J, Peng L. A novel panel based on immune infiltration and tumor mutational burden for prognostic prediction in hepatocellular carcinoma. Aging (Albany NY) 2021;13:8563-87. [PMID: 33714200 DOI: 10.18632/aging.202670] [Reference Citation Analysis]
11 Huo J, Wu L, Zang Y. Development and Validation of a Novel Immune-Gene Pairs Prognostic Model Associated with CTNNB1 Alteration in Hepatocellular Carcinoma. Med Sci Monit 2020;26:e925494. [PMID: 32945289 DOI: 10.12659/MSM.925494] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
12 Giraud J, Chalopin D, Blanc JF, Saleh M. Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies. Front Immunol 2021;12:655697. [PMID: 33815418 DOI: 10.3389/fimmu.2021.655697] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
13 Feng J, Li J, Wu L, Yu Q, Ji J, Wu J, Dai W, Guo C. Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma. J Exp Clin Cancer Res 2020;39:126. [PMID: 32631382 DOI: 10.1186/s13046-020-01629-4] [Cited by in Crossref: 23] [Cited by in F6Publishing: 30] [Article Influence: 11.5] [Reference Citation Analysis]
14 Hibino S, Kawazoe T, Kasahara H, Itoh S, Ishimoto T, Sakata-Yanagimoto M, Taniguchi K. Inflammation-Induced Tumorigenesis and Metastasis. Int J Mol Sci 2021;22:5421. [PMID: 34063828 DOI: 10.3390/ijms22115421] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Zhou HC, Liu CX, Pan WD, Shang LR, Zheng JL, Huang BY, Chen JY, Zheng L, Fang JH, Zhuang SM. Dual and opposing roles of the androgen receptor in VETC-dependent and invasion-dependent metastasis of hepatocellular carcinoma. J Hepatol 2021:S0168-8278(21)00331-7. [PMID: 34004215 DOI: 10.1016/j.jhep.2021.04.053] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Woller N, Engelskircher SA, Wirth T, Wedemeyer H. Prospects and Challenges for T Cell-Based Therapies of HCC. Cells 2021;10:1651. [PMID: 34209393 DOI: 10.3390/cells10071651] [Reference Citation Analysis]
17 Yugawa K, Itoh S, Yoshizumi T, Iseda N, Tomiyama T, Morinaga A, Toshima T, Harada N, Kohashi K, Oda Y, Mori M. CMTM6 Stabilizes PD-L1 Expression and Is a New Prognostic Impact Factor in Hepatocellular Carcinoma. Hepatol Commun 2021;5:334-48. [PMID: 33553979 DOI: 10.1002/hep4.1643] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
18 Inokuchi S, Itoh S, Yoshizumi T, Morinaga A, Toshima T, Takeishi K, Nagao Y, Harada N, Ikegami T, Shimokawa M, Mori M. Prognostic significance of systemic inflammation score in patients who undergo hepatic resection for hepatocellular carcinoma. Langenbecks Arch Surg 2021;406:773-9. [PMID: 33595705 DOI: 10.1007/s00423-021-02103-1] [Reference Citation Analysis]
19 Sun DW, An L, Huang HY, Sun XD, Lv GY. Establishing peripheral PD-L1 as a prognostic marker in hepatocellular carcinoma patients: how long will it come true? Clin Transl Oncol 2021;23:82-91. [PMID: 32462395 DOI: 10.1007/s12094-020-02390-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
20 Tian H, Zhu X, Lv Y, Jiao Y, Wang G. Glucometabolic Reprogramming in the Hepatocellular Carcinoma Microenvironment: Cause and Effect. Cancer Manag Res 2020;12:5957-74. [PMID: 32765096 DOI: 10.2147/CMAR.S258196] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
21 Toshida K, Itoh S, Yoshizumi T, Shimagaki T, Wang H, Kurihara T, Toshima T, Nagao Y, Harada N, Hata K, Makihara Y, Watanabe H, Mori M. Retrospective evaluation of the effect of Ninjin'yoeito in hepatocellular carcinoma patients treated with lenvatinib. Surg Today 2021. [PMID: 34417867 DOI: 10.1007/s00595-021-02358-7] [Reference Citation Analysis]
22 Iseda N, Itoh S, Yoshizumi T, Tomiyama T, Morinaga A, Shimagaki T, Wang H, Kurihara T, Toshima T, Nagao Y, Harada N, Oda Y, Mori M. Lymphocyte-to-C-reactive protein ratio as a prognostic factor for hepatocellular carcinoma. Int J Clin Oncol 2021. [PMID: 34251555 DOI: 10.1007/s10147-021-01985-x] [Reference Citation Analysis]
23 Iseda N, Itoh S, Yoshizumi T, Yugawa K, Morinaga A, Tomiyama T, Toshima T, Kohashi K, Oda Y, Mori M. ARID1A Deficiency Is Associated With High Programmed Death Ligand 1 Expression in Hepatocellular Carcinoma. Hepatol Commun 2021;5:675-88. [PMID: 33860125 DOI: 10.1002/hep4.1659] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Iseda N, Itoh S, Yoshizumi T, Tomiyama T, Morinaga A, Yugawa K, Shimokawa M, Shimagaki T, Wang H, Kurihara T, Kitamura Y, Nagao Y, Toshima T, Harada N, Kohashi K, Baba S, Ishigami K, Oda Y, Mori M. Impact of Nuclear Factor Erythroid 2-Related Factor 2 in Hepatocellular Carcinoma: Cancer Metabolism and Immune Status. Hepatol Commun 2021. [PMID: 34687175 DOI: 10.1002/hep4.1838] [Reference Citation Analysis]
25 Itoh S, Yoshizumi T, Kitamura Y, Yugawa K, Iseda N, Shimagaki T, Nagao Y, Toshima T, Harada N, Kohashi K, Baba S, Ishigami K, Oda Y, Mori M. Impact of Metabolic Activity in Hepatocellular Carcinoma: Association With Immune Status and Vascular Formation. Hepatol Commun 2021;5:1278-89. [PMID: 34278175 DOI: 10.1002/hep4.1715] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]